Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.

@article{Seltzer2003OnceweeklyDV,
  title={Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.},
  author={Elyse Seltzer and Mary Beth Dorr and Beth P Goldstein and Marc Perry and James A. Dowell and Tim Henkel},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2003},
  volume={37 10},
  pages={1298-303}
}
Dalbavancin, a novel glycopeptide with a long elimination half-life ( approximately 9-12 days), was compared to standard antimicrobial therapy for skin and soft-tissue infections (SSTIs). In a randomized, controlled, open-label, phase 2 proof-of-concept trial, adults received 1100 mg of dalbavancin (as a single intravenous infusion), 1000 mg of dalbavancin intravenously and then 500 mg intravenously 1 week later, or a prospectively defined standard-of-care regimen. A gram-positive pathogen was… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 71 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 15 references

Attributes of dalbavancin: well distributed, weekly dosing, and completely eliminated [abstract P1225

  • M Stogniew, F Pu, J. Dowell
  • Clin Microbiol Infect
  • 2003
1 Excerpt

Activity of dalbavancin (BI-397) in vitro and in experimental endocarditis due to methicillinresistant Staphylococcus aureus (MRSA) susceptible or intermediate to glycopeptides (GISA) [abstract B-278

  • A Lefort, J Pavie, L Garry, F Chau, B. Fantin
  • Program and abstracts of the 42nd Interscience…
  • 2002
1 Excerpt

Protein binding of dalbavancin using isothermal titration microcalorimetry [abstract A1385

  • M Cavaleri, A Cooper, MA Nutley, M. Stogniew
  • Program and abstracts of the 42 nd Interscience…
  • 2002
1 Excerpt

Similar Papers

Loading similar papers…